Growth hormone treatment and left ventricular dimensions in Turner syndrome.
J Pediatr
; 150(6): 587-91, 2007 Jun.
Article
em En
| MEDLINE
| ID: mdl-17517238
ABSTRACT
OBJECTIVE:
To determine whether cardiac dimensions were different in girls with Turner syndrome (TS) who received growth hormone (GH) compared with those who did not receive GH. STUDYDESIGN:
This retrospective, cross-sectional study analyzed echocardiograms in 86 females with TS divided into GH-treated (n = 67) and untreated (n = 19) groups. The subjects all participated in the National Institutes of Health protocol between 2001 and 2006.RESULTS:
The average age was 16.2 years (range, 10 to 25 years), and average duration of GH treatment was 4.4 years (range, 1 to 14 years). The GH-treated group was taller by approximately 7 cm (P = .004), but cardiac dimensions normalized to body surface area (BSA), including septal and posterior wall thickness and left ventricular (LV) mass and internal diameters, did not differ significantly between the 2 groups. The fractional shortening index was similar in the 2 groups. Multiple regression analyses indicated that BSA, but not duration of GH treatment, predicted LV dimensions in girls with TS.CONCLUSIONS:
GH treatment of girls with TS increases stature but does not disproportionately affect cardiac dimensions.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Síndrome de Turner
/
Hormônio do Crescimento
/
Hormônio do Crescimento Humano
/
Coração
/
Ventrículos do Coração
Tipo de estudo:
Diagnostic_studies
/
Guideline
/
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article